PubMed Health⌕ Search

PubMed · 15473336

Patch testing for corticosteroid allergy.

Abstract

During the 1990s, contact allergy to topical corticosteroids became a well-recognized complication of dermatologic therapy. Groups of related corticosteroids were subsequently identified on the basis of their chemical structures, and some investigators have found these helpful in identifying potential cross-reactions. The widespread use of hydrocortisone as an over-the-counter medication and its addition to a wide array of topical products make hydrocortisone the most common allergen. Awareness of the risk of corticosteroid allergy and the availability of newer topical immunomodulating agents such as tacrolimus and pimecrolimus may eventually reduce the incidence of contact allergy to corticosteroids. Rokea el-Azhary, MD, PhD, Professor of Dermatology at the Mayo Clinic in Rochester, MN; Erin Warshaw, MD, Associate Professor of Dermatology at the University of Minnesota, Veterans Affairs Medical Center; and Kalman L. Watsky, MD, Associate Clinical Professor, Department of Dermatology, Yale University School of Medicine, and Section Chief of Dermatology, Hospital of Saint Raphael, were invited to give their opinions on strategies for detecting allergens and recommending allergen substitution for patients with suspected topical corticosteroid allergy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rokea el-Azhary, Erin Warshaw, Kalman L Watsky. 2004. Patch testing for corticosteroid allergy.. https://pubmed.ncbi.nlm.nih.gov/15473336/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

[Blindness following reduction of a malar fracture].

Blindness is the most serious injury to the eye following a midfacial fracture. The onset of blindness complicating the midfacial fracture may be immediate (with the trauma), delayed (hours to days), or postoperative. The incidence of postoperative blindness lies between 0.3 and 8.3%. There are multiple mechanisms responsible for blindness but the most common reason with about 66% is probably increased intraorbital pressure attributable to intraorbital hemorrhage. The management of surgical decompression of the orbit for acute blindness is essential when treatment of a midfacial fracture is intended. Acute orbital compartment syndrome can effectively be relieved by lateral canthotomy and cantholysis and administration of high doses of corticosteroids. Further possibilities of surgical decompression of the orbit are discussed in this case report with postoperative irreversible blindness after reduction of a malar fracture and rapidly performed surgical decompression.

Adrenal Cortex Hormones↗